David Stern Appointed CEO of Kindbody to Drive Future Growth and Innovation in Fertility Care

Kindbody Appoints David Stern as New Chief Executive Officer

In a significant move for the evolving landscape of reproductive healthcare, Kindbody, a leading fertility clinic network in the United States, has announced the appointment of David Stern as its new Chief Executive Officer. This decision comes as part of Kindbody's strategy to navigate the next stage of growth for the company, which currently operates a network of 27 state-of-the-art clinics and IVF laboratories, reaching patients across 113 countries.

Having garnered over thirty years of experience specifically within women's healthcare and fertility sectors, Stern is poised to lead Kindbody into a new era marked by innovation and improved accessibility to fertility care. Linda Mintz, Chairperson of Kindbody's Board of Directors, expressed confidence in Stern’s leadership, emphasizing his unique position to steer the company as reproductive healthcare takes center stage in national discussions. She stated, “David's unparalleled leadership uniquely positions him to lead Kindbody into a bold new era of growth and innovation.”

Prior to joining Kindbody, Stern held the role of CEO at Boston IVF for five years, which is recognized as one of the largest fertility networks in the United States. His vast experience in progressive leadership roles is underscored by his successful tenure at Symbiomix Therapeutics, where he led its transition from development to market and its eventual acquisition by Lupin Pharmaceuticals. Moreover, his previous roles at Merck Serono and EMD Serono provided him with extensive expertise in global fertility markets and biopharmaceutical management.

As CEO of Kindbody, Stern will focus on continuing the organization's mission of making fertility care accessible and affordable to all individuals. He remarked, “I am truly honored to join a company that has set the standard for innovation and leadership in reproductive healthcare.” Stern is excited to build upon Kindbody's robust foundation and facilitate growth initiatives that include strengthening operational infrastructures and investing in adept teams that align with the organization’s forward-looking vision.

Kindbody is noted for its unique model, being both a family-building benefits provider for employers and an operator of its own clinics. This integrated approach seeks to streamline the patient experience and ensure quality outcomes at lower costs. The firm’s reputation for excellence has garnered recognition, placing it on prestigious lists such as the CNBC Disruptor 50 and Fast Company’s Brands that Matter.

Founded in 2018, Kindbody has attracted over $315 million in funding, which emphasizes investor confidence in its innovative approach to fertility services. As it embarks on this new chapter under Stern's guidance, Kindbody aims to expand its offerings and make significant impacts in the fertility space, advocating for widespread awareness and improved access to essential healthcare services.

Stern holds an MBA in International Marketing and Management from Babson College, along with a Bachelor of Science degree in Biology from Brandeis University. With his extensive background and experience, David Stern is expected to drive Kindbody towards new milestones in patient-centered care and healthcare technology advancements, aligning with the company’s mission of transforming fertility care for a diverse range of patients across the globe.

For more information about Kindbody and its services, visit www.kindbody.com.